Price T Rowe Associates Inc Keros Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 43,227 shares of KROS stock, worth $620,739. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,227
Previous 909,707
95.25%
Holding current value
$620,739
Previous $14.4 Million
96.94%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding KROS
# of Institutions
177Shares Held
36.5MCall Options Held
938KPut Options Held
1.39M-
Nuveen, LLC Charlotte, NC3.95MShares$56.7 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.6MShares$37.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.57MShares$36.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.51MShares$36.1 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA2MShares$28.7 Million3.97% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $370M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...